Tango, Revolution Pancreatic Cancer Drug Combo Shows
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Tango Therapeutics reports that its drug vopimetostat, combined with Revolution Medicines’ daraxonrasib, produced durable responses in the large majority of pancreatic cancer patients in an early-stage trial
- Revolution Medicines’ daraxonrasib is part of a combination therapy showing unprecedented response rates in pancreatic cancer, building on recent data that highlighted its standalone performance
- Early-stage clinical trial data reveal high and durable response rates, marking a potential shift in treating pancreatic cancer, a disease historically resistant to many therapies
Why it matters: Patients with pancreatic cancer, who typically face low response rates to treatment, may now have a promising new combination therapy; the results could accelerate clinical development timelines for both companies' drugs.
Ask SkimNews
